Posts Tagged by health care

NuGEN Launches BaseSpace Cloud App to Help Streamline NGS Analysis

 Sequence data generated with NuGEN’s target enrichment technology can be processed in BaseSpace using new app to mark duplicates and perform quality trimming
San Carlos, CA -OCT. 6– NuGEN Technologies is pleased to announce that scientists and clinicians using its Ovation Target Enrichment System to prepare biologic samples for genomic analysis can now process resulting sequence data in BaseSpace–a cloud computing platform, hosted by Illumina, Inc.
“NuGEN’s new Ovation Target Enrichment System Data Processing Application will allow the large community of Illumina sequence platform users to further streamline the rapid and convenient workflow of our Ovation Target Enrichment System products,” said Alan Dance, VP of Marketing at NuGEN.

The Ovation Target Enrichment product line employs Single Primer Enrichment Technology (SPET), a novel approach for enrichment of genomic DNA targets or cDNA for RNA target regions. SPET products allow researchers and clinicians to quickly and accurately enrich biologic samples for sensitive detection of a wide range of genomic markers including mutations, SNPs, indels, gene fusions, alternately spliced transcripts and copy number variants.

The new NuGEN-application, published on BaseSpace on September 30, provides an intuitive user interface for uploading sequence data. The application performs quality trimming and probe trimming on the parsed data – removing data derived from bases with low sequencing quality scores and aligning high quality data to the UCSC human reference genome.
Subsequently, PCR duplicate reads created during the library amplification process are identified using a random N6 sequence, unique to the Ovation Target Enrichment System workflow positioned adjacent to the barcode index.

Output files from the Ovation Target Enrichment System Data Processing Application for BaseSpace include processed BAM files with PCR duplicates removed or marked, processed FASTQ files with duplicates removed, and UCSC bigWig tracks with duplicates removed for visualization using the UCSC human genome browser.

For full details, visit http://www.nugen.com/content/ovation-target-enrichment-system-data-processing-application.
NuGEN Technologies Inc. is a rapidly-growing, privately-held company providing innovative products and systems for the preparation of biologic samples for targeted genomic analysis. Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries.
Media Contact:
Anita Harris, Harris Communications Group

The Harris Communications Group is an award-winning PR and marketing firm specializing in outreach for health care, life sciences and technology, worldwide.

 

Scientia Advisors Names Randy Goodman Manager of Pricing and Market Access Group

Pleased to post the press release we wrote for Scientia Advisors–
–Anita Harris

Health economics, policy & reimbursement expert to help healthcare, diagnostics, biotech, medical device, health IT and pharma companies bring products to market

Randy Goodman, PhD, a nationally recognized expert in pricing, reimbursement and managed care, has joined global strategy firm Scientia Advisors as manager of the firm’s Pricing and Market Access Group, Scientia Advisors announced, today.
Scientia Advisors is a global management consulting firm specializing in strategy, operations and pricing/reimbursement for major and emerging companies in healthcare, life sciences, pharma, biotechnology, and health IT. The firm’s Pricing and Market Access Group helps companies determine how best to introduce and develop pricing structures, and obtain reimbursement from third-party payers–within a context of highly competitive industries and rapidly changing health and regulatory systems, worldwide.
“Dr. Goodman comes to Scientia with a wealth of experience in the managed care, medical device, and biotech industries,” said Harry Glorikian, Scientia Advisors’ founder and managing partner. “He has directed pricing, reimbursement and managed markets strategies for a variety of US and global healthcare and device companies and has served as a consultant to the White House on health reform. We are delighted to welcome him to our firm.”
Immediately before joining Scientia, Dr. Goodman was Consultant/Director of health economics, reimbursement, managed markets and government relations for Welldoc, Inc., a leading provider of mobile health diabetes solutions in the US.
Previously, he served in a similar capacity for medical device/equipment companies ImpediMed, Inc., in San Diego; Access Mediquip, LLC, in Houston; and Hoveround,Corporation, in Sarasota. At–where, at various times, he has overseen he oversaw and managed strategic development, financial analysis, clinical reimbursement policy, regulation and financial analysis, business development, sales and marketing, among other duties.
Dr. Goodman served as a Health Care Reform Policy Consultant to the White House Office of Health Reform in 2009 and 2010 and counseled and collaborated with the White House and Congress on health reform proposals in 1992 and 1993.
He holds a PhD in Health Policy and Master of Health Administration from Harvard University and a BA from the University of Texas. He is a fellow in the American College of Healthcare Executives, a Director of the National Association of Specialty Health Organization, among other affiliations.

Scientia Advisors, headquartered in Cambridge, Massachusetts, is a global management consulting firm specializing in growth, operations and pricing/reimbursement strategies for companies operating across the healthcare industry value chain. Strategies developed by Scientia Advisors are fueling growth of the leading firms in biotechnology, medical devices, diagnostics, pharmaceuticals, and health and nutrition.

Anita Harris is managing director of the Harris Communications Group, an award-winning PR, digital and content marketing firm based in Cambridge, MA.

Harris Communications Advisor Robert Langer Founds Blend Therapeutics

Life Science Startup to  Target Multiple Disease Mechanisms

I’m pleased to report that Harris Communications Group Advisory Board Member Robert Langer of MIT is involved in yet another life science startup.

It’s a biotech company called “Blend Therapeutics” that will develop a new class of medicines possessing  “unprecedented ability to precisely control each agent’s therapeutic action in concert… ”  The goal is to   “predictably, effectively, and safely target the multiple mechanisms underlying complex diseases, ” according to a press release.

Blend was founded by three leaders in the fields of chemistry and nanomedicine:  Langer, who is David H. Koch Institute Professor at the Massachusetts Institute of Technology;   Stephen J. Lippard, PhD, Arthur Amos Noyes Professor of Chemistry at MIT; and Omid Farokhzad, MD, Director of the Laboratory of Nanomedicine and Biomaterials and Associate Professor of Anesthesia, Brigham and Women’s Hospital and Harvard Medical School.

Blend has received financial backing from  Flagship Ventures, New Enterprise Associates and NanoDimension.

Langer said:  ” We see unparalleled opportunity to translate innovative science into important drugs for patients in need, and we’re excited by the strength of our founding investors and management who share our vision of building a successful biotechnology company that is foremost about improving the lives of patients.”

In addition to Langer, Lippard and Farokhhzad,  Blend’s  Scientific Advisory Board includes eight thought leaders in the fields of chemistry, cancer biology, immunology and medicine:

• Dennis Ausiello, MD, Chief of Medicine and Jackson Professor of Clinical Medicine, Massachusetts General Hospital and Harvard Medical School

• Philip Kantoff, MD, Chief Clinical Research Officer and Professor of Medicine, Dana Farber Cancer Institute and Harvard Medical School
• Alexander Klibanov, PhD, Novartis Professor of Chemistry and Bioengineering, Massachusetts Institute of Technology;
• Ulrich von Andrian, MD, PhD, Mallinckrodt Professor of Immunopathology, Harvard Medical School
• Bruce R. Zetter, PhD, Charles Nowiszerski Professor of Cancer Biology, Children’s Hospital Boston and Harvard Medical School.

MaestroTM is a trademark of Blend Therapeutics, Inc. More information is available at http://www.blendtx.com.

 

—Anita M. Harris

Anita Harris is the president of  Harris Communications Group, a  Cambridge, MA  public relations firm specializing in strategic marketing communications,  thought leadership and social media for companies involved in health, science, technology and energy, worldwide. She also blogs at newcambridgeobsersver.com.